Privacy preferences
Inderes uses cookies to provide a better user experience and a personalised service. By consenting to the use of cookies, we can develop an even better service and will be able to provide content that is interesting to you.
  • Forum
  • Premium
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Morning ReviewDaily market recap and key overnight highlights
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • PortfolioInderes model portfolio
    • FemmeBreaking barriers and building confidence in investing
  • Learn about investing
    • Analysis SchoolLearn how to read and understand stock analysis
    • Investing SchoolGuides and lessons to grow your investing knowledge
    • Portfolio buildersInvesting knowledge for every level, from first steps to advanced portfolio strategies.
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
    • Earnings SeasonCompare EPS estimates to reported results
    • Insider TransactionsTrack buying and selling activity by company insiders
    • Short SellingSee which listed companies have disclosed short interest
    • Virtual Analyst ChatAsk questions and get instant AI-powered investment insights
    • Compound Interest CalculatorSee how your savings grow with the power of compound interest.
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • Instagram
  • X (Twitter)
  • Tiktok
  • Linkedin
Get in touch
  • info@inderes.fi
  • +358 10 219 4690
  • Porkkalankatu 5
    00180 Helsinki
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Q&A
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

Log in to your Inderes Free account to see all free content on this page.
Create account

Paxman

58.70 SEK-1.84 %23.9. klo 11.22
Less than 1K followers

PAX

First North Stockholm

Medical Equipment & Services

Health Care

Overview
Financials & Estimates
Ownership
Dividend
Short Selling
Investor views
Compare
-1.84 %
+6.73 %
+17.40 %
+33.41 %
+4.45 %
-17.79 %
+76.28 %
+23.58 %
+438.53 %

Paxman is active in scalp cooling, which is used for patients undergoing chemotherapy. The company's product Paxman Scalp Cooler is used to minimize hair loss in patients during treatment. The Scalp Cooler is a freestanding, mobile and electrically powered cooling unit that cools the patient's scalp via a cooling cap. Paxman was founded in 1996 and is headquartered in Karlshamn.

Read more
Market cap
1.37B SEK
Turnover
81.96K SEK
Revenue
EBIT %
P/E
Dividend yield-%
Revenue and EBIT-%
EPS and dividend
Financial calendar
20.11.
2026

Interim report Q3'26

All
Press releases
ShowingAll content types

Revenue and EBIT-%

Revenue M

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Press release25.08.2026 klo 18.51

DNB Carnegie Access: Paxman: IBBM wheels keep on turning – Q2 review

Paxman
Press release24.08.2026 klo 13.08

Redeye: Paxman (Q2 Review): Strong report boosts confidence in the outlook

Paxman
Press release21.08.2026 klo 12.00

PAXMAN's presentation of the Q2 2026 report is now available to watch on demand.

Paxman

Join Inderes community

Don't miss out - create an account and get all the possible benefits

FREE account
Stock market's most popular morning newsletter
Analyst comments and recommendations
Stock comparison tool
PREMIUM account
All company reports and deep analyses
Premium tools: model portfolio, screener, insider transactions
Premium columns: Guest column, expert insights
Inderes MCP - Inderes data directly into your AI tools
Create account
Press release21.08.2026 klo 08.41

DNB Carnegie Access: Paxman: IBBM delivers – Q2 initial

Paxman
Regulatory press release21.08.2026 klo 08.00

PAXMAN publishes its interim report for Q2 2026

Paxman
Press release17.08.2026 klo 17.10

Invitation: Live Presentation with Richard Paxman – Q2 2026

Paxman
Press release10.08.2026 klo 17.23

DNB Carnegie Access: Paxman: FDA says De Novo is the appropriate route for CIPN device

Paxman
Press release10.08.2026 klo 15.20

Paxman Announces FDA Regulatory Progress for Limb Cryocompression System

Paxman
Press release10.08.2026 klo 12.01

DNB Carnegie Access: Paxman: Beyond Dignitana – Q2 preview

Paxman
Press release16.07.2026 klo 17.54

DNB Carnegie Access: Paxman: CMS proposed rules – directionally positive

Paxman
Press release16.07.2026 klo 17.00

CMS Proposes Important Medicare Payment Policy Change for Mechanical Scalp Cooling

Paxman
Press release14.07.2026 klo 10.33

DNB Carnegie Access: Paxman: CIPN regulatory clearance in the EU and UK

Paxman
Press release14.07.2026 klo 10.00

Paxman Expands Global Regulatory Certifications for Cryocompression Device for Prevention of Chemotherapy-induced Peripheral Neuropathy (CIPN)

Paxman
Regulatory press release22.05.2026 klo 12.05

Press release from PAXMAN AB’s 2026 Annual General Meeting

Paxman
Press release22.05.2026 klo 08.29

DNB Carnegie Access: Paxman: IBBM on track and CIPN catalyst pending – Q1 review

Paxman
Press release21.05.2026 klo 13.07

Redeye: Paxman (Q1 Initial take): In line with expectations

Paxman
Press release21.05.2026 klo 09.21

DNB Carnegie Access: Paxman: Clean beat to start the year – Q1 initial

Paxman
Regulatory press release21.05.2026 klo 08.00

PAXMAN publishes its interim report for Q1 2026

Paxman
Press release20.05.2026 klo 11.00

Invitation: Live Presentation with Richard Paxman – Q1 2026

Paxman
Press release12.05.2026 klo 12.47

Redeye: Paxman (Q1 Preview): First CPT1 quarter

Paxman